Vitrakvi approved for cancers with specific genetic biomarker
Tuesday, November 27, 2018 - 23:00
in Health & Medicine
Vitrakvi, or larotrectinib, has been approved by the U.S. Food and Drug Administration to treat cancers with a specific inherited trait called a biomarker.